The body‘s response to injury is a very specific and well documented series of steps collectively referred to as the ”Healing Cascade”. This cascade is comprised of several distinct phases. The natural healing process requires a systems approach that combines the use of Growth Factors and Stem Cells integrated into a Matrix to optimize bone/ tissue repair and regeneration.The use of these bioactive cells to augment and accelerate the natural healing process is considered by many to be a “new frontier” of clinical treatment.
Autologous Platelet Concentrate is a specific concentration of platelets and plasma that can be directly delivered to any surgical wound to create the conditions to accelerate healing.
The early stages of the healing cascade are primarily mediated by platelets and the release of cellular growth factors.
Platelet-Derived Growth Factor (PDGF):
• Initiates connective tissue healing
• Increases mitogenesis, angiogenesis, and macrophage activation
Vascular Endothelial Growth Factor (VEGF):
• P ossess potent angiogenic, mitogenic, and vascular permeability enhancing activities
Transforming Growth Factor-ß (TGF-ß):
• Increases chemotaxis and mitogenesis
• S timulates deposition of collagen
Epidermal Growth Factor (EGF):
• Induces epithelial development
• P romotes angiogenesis Chemomigration
As the wound continues to mature, healing progresses by attracting stem cells
from the periphery into the affected area.
Autologous Platelet Concentrate contains high concentrations of growth factors within alpha-granule releasate.
This initiates a cascade that results in chemoattraction of circulating stem cells promoting differentiation (proliferation),to develop into mature tissues.
“Platelet concentrate appears to have potent antimicrobial capacity against staphyloccus aurreus
platelet concentrate might represent a useful strategy against post operative infections.”
Moojen: University Medical Center Utrecht, Dept. of Orthopaedics, Utrecht, NL
“Platelets can exert a variety of biological functions, one of which is to combat invading microorganisms.”
Zaat: CINIMA (Center of Infection and Immunity Amsterdam), Academic Medical Center, Amsterdam, NL
Oral Surgery: Sinus Lift Bone Grafting
“Bone grafts with growth factors from PRP demonstrated greater trabicular bone density than bone grafts without PRP (74% vs. 55%).”
Marx: Oral Surg Oral Med Oral Path 1998;85:638-46
Cosmetic Surgery: Abdominalplasty
“The use of PRP in abdominoplasty procedures resulted in fewer seromas wounds healed more
rapidly and with a more esthetic result.”
Jackson: Amer Jour Cos Surg Vol.20, No.4, 2003
Cosmetic Surgery: Face Lift
“The use of autologous fibrin glue and platelet gel resulted in shorter operating times, elimination of drains, compressive dressings reductions, reduction of pain and post-op swelling and improved wound healing with resultant shorter recovery time.”
Man: Aesth Plast Surg, June 2000
Cardiac: Sternal Closure
“The incidence of superficial infection was significantly lower in the PRP group compared with control.
There was a similar relationship found when comparing deep sternal wound infections.”
Towbridge: JECT 2005;37:381-386
Sports Medicine: Lateral Epicondylitis/Tennis Elbow
“PRP therapy is as effective as surgery, with sustained and significant improvement over time, no side effects, and high patient acceptance.”
Mishra: Treatment of Chronic Severe Elbow Tendinosis with PRP. Am J Sports Med 2006;34:1774-1778
Podiatry: Plantar Fasciitis
“Injecting into recalcitrant, symptomatic plantar fascia may cause a reparative effect leading
to a resolution of symptoms.”
Barrett: Growth Factors for Chronic Plantar Fasciitis. Podiatry Today, Nov 2004
Sports Medicine: ACL Repair
“Knees that received (platelet) gel showed greater defect filling and increased mechanical strength compared to untreated knees.”
Murray: Use of collagen-PRP scaffold to stimulate healing. J Orth Res 2006;24:820-83
Chronic Wound: Diabetic Foot Syndrome
“More patients treated with PRP achieved complete wound healing (55% vs. 24%) than in the
control group (pThe frequency and severity of adverse events (infection and vascular complications) was
significantly higher in the control group (9 vs. 2, p=0,02).“
Friese: 5th Int´l symposium on the diabetic foot, Noordwijkerhout, NL 2007
MED&CARE Sp. z o.o.
ul. Mławska 13
81-204 Gdynia, Poland
phone: +48 58 776 22 75
fax: +48 58 350 97 57
mobile: +48 506 399 272
Number: PL 92 1020 1853 0000 9502 0124 1017
Bank PKO BP SA, I Oddział w Gdyni
Kod BIC (Swift): BPKOPLPW